Covance Not Cooling...
Health Care: Drugs
Progenics Pharmaceuticals Inc. (PGNX: NASDAQ)
$4.31 0.18 | 4.36%
05/17/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 4.31 |
| 52 Week High | 11.00 |
| 52 Week Low | 1.41 |
| Avg. Daily Vol. (Mil) | 0.47 |
| Beta (3 year) | 1.51 |
| Share Related Items | |
| Mkt Cap (Mil) | 219.98 |
| Shares Out (Mil) | 51.04 |
| Float (Mil) | 32.31 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 6.80 |
| Current Ratio | 7.00 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 15.64 |
| Price/Book | 3.27 |
| Price/Cash Flow | -4.80 |
| Per Share Data | |
| Earnings | -0.85 |
| Sales | 0.28 |
| Book Value | 1.32 |
| Cash Flow | -0.89 |
| Business Summary | |
|---|---|
| Progenics Pharmaceuticals, Inc. develops and commercializes therapeutics for patients suffering from cancer and related conditions. | |
| General Information | |
| 777 Old Saw Mill River Road
Tarrytown, NY 10591 |
|
| www.progenics.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 76 | |
| CEO: Mr. Mark R. Baker | |
| Short Interest | |
| Current Month (Mil) | 1.91 |
| Previous Month (Mil) | 1.69 |
| Short Interest Ratio (Days) | 5.60 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -44.30 |
| Return on Investments | -69.00 |
| Profitability | |
| Gross Margin | 96.90 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with PGNX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorDrugs Facing FDA Approval i...
- UserGFNN Stockdiagnostics 14
- ContributorStocks Rising On Unusual Vo...
- ProTudor Investment
- ContributorStocks At New 52-Week Highs...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks At New 52-Week Highs...
Latest PGNX Headlines from TheStreet
- Progenics Pharmaceuticals Added To The NASDAQ Biotechnology Index 05.17.13 | 05:05 pm
- Progenics Pharmaceuticals Announces First Quarter 2013 Financial Results 05.10.13 | 07:05 am
- Progenics Pharmaceuticals To Host Conference Call To Review First Quarter 2013 Financial Results On May 10 05.06.13 | 05:05 pm
- Short Interest Moves 19% Higher For PGNX 04.25.13 | 04:04 pm
- Progenics Pharmaceuticals To Present At Needham Healthcare Conference 04.24.13 | 05:04 pm
- 'Mad Money' Lightning Round: I Like Priceline 04.02.13 | 06:04 am
- Cramer's 'Mad Money' Recap: Checking My List 04.01.13 | 07:04 pm
- Progenics Pharmaceuticals Announces Fourth Quarter And Year-End 2012 Financial Results 03.15.13 | 07:03 am
- Progenics Pharmaceuticals To Host Conference Call To Review Fourth Quarter Financial Results On March 15 03.08.13 | 03:03 pm
- 5 Stocks Under $10 Set to Soar 03.07.13 | 01:03 pm
Press Releases for PGNX
- MedImmune Announces Agreement With Progenics Pharmaceuticals To Develop Therapies Against Serious Bacterial Infections - PR Newswire 12.17.12 | 09:12 am
- Salix And Progenics Receive Complete Response Letter From FDA For RELISTOR® SNDA - Business Wire 07.27.12 | 07:07 pm
- Salix And Progenics Announce Positive Highly Statistically Significant Results Of Oral Methylnaltrexone For Phase 3 Trial In Chronic, Non-Cancer Pain Subjects With Opioid-Induced Constipation - Business Wire 12.20.11 | 07:12 am
- Progenics And Salix Announce FDA Acceptance Of SNDA Filing For RELISTOR® In Patients With Non-Cancer Pain - Business Wire 08.30.11 | 07:08 am
- Progenics Pharmaceuticals To Webcast Upcoming Presentations - Business Wire 04.04.11 | 08:04 am
- Progenics Pharmaceuticals Announces Fourth Quarter And Year-End 2010 Financial Results - Business Wire 03.15.11 | 08:03 am
- Progenics Pharmaceuticals Announces Changes In Executive Responsibilities - Business Wire 03.09.11 | 07:03 am
- Progenics Reports Positive Preliminary Data From Ongoing Phase 1 Clinical Study Of PSMA ADC - Business Wire 02.17.11 | 04:02 pm
- Salix Pharmaceuticals And Progenics Pharmaceuticals Announce Worldwide License Agreement For RELISTOR® - Business Wire 02.07.11 | 07:02 am
- Progenics Pharmaceuticals And Salix Pharmaceuticals Announce Worldwide License Agreement For RELISTOR® - Business Wire 02.07.11 | 07:02 am
Partner Headlines for PGNX
- Progenics Pharmaceuticals Earnings: Everything You Must Know Now - Wall St. Cheat Sheet 05.10.13 | 09:05 am
- 5 Healthcare Companies With Recent Insider Buying - Seeking Alpha 11.18.12 | 09:11 am
- 5 Stocks That Dropped the Most Since Gurus Bought Them - NASDAQ 09.13.12 | 07:09 pm
- Another Delay for Salix Candidate - Analyst Blog - NASDAQ 09.10.12 | 10:09 pm
- Another Delay for Salix Candidate - Analyst Blog - Zacks 09.10.12 | 06:09 pm
- Stock Futures Mixed; Salix, Progenics Tumble - Investor's Business Daily 07.30.12 | 09:07 am
- Positive Data on Theravance Drug - Analyst Blog - Zacks 07.11.12 | 06:07 pm
- The Zacks Analyst Blog Highlights: US Airways Group, United Continental Holdings, Delta Airlines, Salix Pharmaceuticals and Progenics Pharmaceuticals - Press Releases - Zacks 04.24.12 | 09:04 am
- What's It Going To Take To Get Salix Cheap? - Seeking Alpha 02.29.12 | 08:02 am
- Progenics Should Outperform The Market In The Short Term - Seeking Alpha 02.15.12 | 08:02 am
